Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease

Peptides

Volumn 27, Issue 12, 2006, Pages 3363-3369

  Iores Marçal, Lígia M ^a   Viel, Tânia A ^b   Buck, Hudson Sousa ^b   Nunes, Viviane A ^a   Gozzo, Andrezza J ^a   Cruz Silva, Ilana ^a   Miranda, Antonio ^a   Shimamoto, Kazuaki ^c   Ura, Nobuyuki ^c   Araujo, Mariana S ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Amyloid; Bradykinin; Kallikrein kinin system; Kininase

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; ARGINYLPROLYLPROLINE; BRADYKININ; PROLYL ENDOPEPTIDASE; TRIPEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN TISSUE; BRAIN VENTRICLE; CEREBROSPINAL FLUID; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME MECHANISM; EXPERIMENTAL MODEL; HISTOLOGY; INFUSION; LIQUID CHROMATOGRAPHY; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RADIOIMMUNOASSAY; RAT; REVERSED PHASE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

ALZHEIMER DISEASE; ANIMALS; BRADYKININ; BRAIN; DISEASE MODELS, ANIMAL; RATS;

ANIMALIA;

EID: 33750942476     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.08.012     Document Type: Article

References (32)

1. Ahmed M.M., Arif M., Chicuma T., and Kato T. Pentylenetetrazol-induced seizures affect the levels of prolyl oligopeptidase, thimet oligopeptidase and glial proteins in rat brain regions, and attenuation by MK-801 pretreatment. Neurochem Int 47 (2005) 248-259
2. Aoyagi T., Wada T., Nagai M., Kogima F., Harada S., Takeuchi T., et al. Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease. Experientia 46 (1990) 94-97
3. Bergamaschini L., Donarini C., Gobbo G., Parnetti L., and Gallai V. Activation of complement and contact system in Alzheimer's disease. Mech Ageing Dev 122 (2001) 1971-1983
4. Bhoola K.D., Figueroa C.D., and Worthy K. Bioregulation of kinins: kallikreins, kininogens and kininases. Pharmacol Rev 44 (1992) 1-80
5. Carretero O.A., Oza N.B., Scigli A.G., and Schork A. Renal tissue kallikrein, plasma renin and plasma aldosterone in renal hypertension. Acta Physiol Lat Am 24 (1974) 448-452
6. Cyr M., Lepage Y., Blais Jr. C., Gervais N., Cugno M., Rouleau J.L., et al. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol 281 (2001) H275-H283
7. Davie E.W., and Ratnoff O.D. Waterfall sequence for intrinsic blood clotting. Science 145 (1964) 1310-1312
8. Frautschy S.A., Horn D.L., Sigel J.J., Harris-White M.E., Mendonza J.J., Yang F., et al. Protease inhibitor coinfusion with amyloid β-protein results in enhanced deposition and toxicity in rat brain. J Neurosci 18 (1998) 8311-8321
9. Gibson A., Edwardson J.A., and Mcdermot T. Postmortem levels of some brain peptidases in Alzheimer's disease: reduction in proline endopeptidase activity in cerebral cortex. Neurosci Res Commun 9 (1991) 73-81
10. Gozzo A.J., Nunes V.A., Carmona A.K., Nader H.B., von Dietrich C.P., Silveira V.L., et al. Glycosaminoglycans affect the action of human plasma kallikrein on kininogen hydrolysis and inflammation. Int Immunopharmacol 2 (2002) 1861-1865
11. Griffiths E.C. Clinical applications of thyrotropin-releasing hormone. Clin Sci 73 (1987) 449-457
12. Huston J.P., and Hasenöhrl R.U. The role of neuropeptides in learning: focus on the neurokinin substance P. Behav Brain Res 66 (1995) 117-127
13. Ichai C., Chevallier N., Delaere P., Dournaud P., Epelbaum J., Hauw J.J., et al. Influence of region-specific alterations of neuropeptidase content on the catabolic fates of neuropeptides in Alzheimer's disease. J Neurochem 62 (1994) 645-665
14. Joseph K., Shibayama Y., Nakazawa Y., Peerschke E.I., Ghebrehiwet B., and Kaplan A.P. Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease. Immunopharmacol 43 (1999) 203-210
15. Kariya K., Yamauchi A., and Sasaki T. Regional distribution and characterization of kinin in the CNS of the rat. J Neurochem 44 (1985) 1892-1897
16. Li Z., Tyor W.R., Xu J., Chao J., and Hogan E.L. Immunohistochemical localization of kininogen in rat spinal cord and brain. Exp Neurol 159 (1999) 528-537
17. Madeddu P., Parpaglia P.P., Demontis M.P., Varoni M.V., Fattaccio M.C., Anania V., et al. Early blockade of bradykinin B2-receptors alters the adult cardiovascular phenotype in rats. Hypertension 25 (1995) 453-459
18. Malavazi-Piza K.C., Araújo M.A., Godinho R.O., and Tanaka A.S. Effect of invertebrate serine proteinase inhibitors on carageenan-induced pleural exudation and bradykinin release. Int Immunopharmacol 4 (2004) 1401-1408
19. Nitsch R.M., Kim C., and Growdon J.H. Vasopressin and bradykinin regulate secretory processing of the amyloid protein precursor of Alzheimer's disease. Neurochem Res 23 (1998) 807-814
20. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 4th ed. (1998), Academic Press, San Diego
21. Raidoo D.M., and Bhoola K.D. Kinin receptors on human neurons. J Neuroimmunol 77 (1997) 39-44
22. Raidoo D.M., and Bhoola K.D. Pathophysiology of the kallikrein-kinin system in mammalian nervous tissue. Pharmacol Ther 79 (1998) 105-127
23. Ramirez-Molina C., Heudi O., Pullen M., and Marshall P.S.J. Study of bradykinin metabolism by rat lung tissue membranes and rat kidney brush border membranes by HPLC with inductively coupled plasma-mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. Pept Sci 12 3 (2006) 220-226
24. Shimamoto K., Ando T., Tanaka S., and Imura O. The determination of kinin and glandular kallikrein in human biological fluids. Atemwegs- Lungenkr Jahrgang 14 (1988) S29-S36
25. Shimamoto K., Ando T., Tanaka S., Nakahashi Y., Nishitani T., Hosoda S., et al. An improved method for the determination of human blood kinin levels by sensitive kinin radioimmunoassay. Endocrinol Jpn 29 (1982) 487-494
26. Taylor W.L., and Dixon J.E. Catabolism of neuropeptides by a brain proline endopeptidase. Biochem Biophys Res Commun 94 (1980) 9-15
27. Toide K., Shinoda M., Iwamoto Y., Fujiwara T., Okamiya K., and Uemura A. A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res 83 (1997) 147-151
28. Turner A.J., Fisk L., and Nalivaeva N.N. Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. Ann NY Acad Sci 1035 (2004) 1-20
29. Vardy E.R., Catto A.J., and Hooper N.M. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med 11 10 (2005) 464-472
30. Walker K., Perkins M., and Dray A. Kinins and kinin receptors in the nervous system. Neurochem Int 26 (1995) 1-16
31. Wenk G.L. Neuropathologic changes in Alzheimer's disease: potential targets for treatment. J Clin Psychiatry 67 3 (2006) 3-7
32. Wilk S. Prolyl endopeptidase. Life Sci 33 (1983) 2149-2157